Disease · HP_0000975

Hyperhidrosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Hyperhidrosis. Diseases, record HP_0000975. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000975

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Hyperhidrosis
Open Targets ID: HP_0000975
Other names: Diaphoresis, Excessive sweating, Increased sweating, Profuse sweating, Sweating, Sweating profusely, Sweating, increased
Highest stage of its drugs: Approval, for 3 of its 15 drugs, from DailyMed, FDA and TTD

Source Open Targets

Drugs15

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SOFPIRONIUM BROMIDE	CHEMBL3707223	Small molecule	Approval	FDA	6	5	5	Drugs and targets
GLYCOPYRRONIUM TOSYLATE	CHEMBL3707243	Small molecule	Approval	DailyMed and FDA	2	0	0	Drugs and targets
PROPANTHELINE	CHEMBL1180725	Small molecule	Approval	TTD	1	0	0	Drugs and targets
GLYCOPYRRONIUM	CHEMBL1201335	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
ONABOTULINUMTOXINA	CHEMBL1201574		Phase 3	ClinicalTrials.gov	3	3	2	Drugs and targets
ALUMINUM CHLORIDE	CHEMBL3833314	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
OXYBUTYNIN	CHEMBL1231	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
GLYCOPYRRONIUM BROMIDE	CHEMBL1201027	Small molecule	Phase 2	ClinicalTrials.gov	3	3	2	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DEXMECAMYLAMINE	CHEMBL2103881	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 15

See all 15 drugs

Targets22

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CHRM3	Muscarinic acetylcholine receptor	6	Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor inhibitor	Approval	https://conductscience.org/library/genes/1131	Drugs and targets
CHRM1	Muscarinic acetylcholine receptor	5	Muscarinic acetylcholine receptor M1 antagonist; Muscarinic acetylcholine receptor inhibitor	Approval	https://conductscience.org/library/genes/1128	Drugs and targets
CHRM2	Muscarinic acetylcholine receptor	5	Muscarinic acetylcholine receptor M2 antagonist; Muscarinic acetylcholine receptor inhibitor	Approval	https://conductscience.org/library/genes/1129	Drugs and targets
CHRM4	Muscarinic acetylcholine receptor	3	Muscarinic acetylcholine receptor inhibitor	Approval	https://conductscience.org/library/genes/1132	Drugs and targets
CHRM5	Muscarinic acetylcholine receptor	3	Muscarinic acetylcholine receptor inhibitor	Approval	https://conductscience.org/library/genes/1133	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	2	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 3	https://conductscience.org/library/genes/6616	Drugs and targets
ADRA1A	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 antagonist	Unknown	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 antagonist	Unknown	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha-1	1	Adrenergic receptor alpha-1 antagonist	Unknown	https://conductscience.org/library/genes/146	Drugs and targets
CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	1	Neuronal acetylcholine receptor; alpha4/beta2 antagonist	Phase 2	https://conductscience.org/library/genes/1137	Drugs and targets

1 to 10 of 22

See all 22 targets

Trials22

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02553798	Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis	Phase 3	564	2018-09-25	Hyperhidrosis	GLYCOPYRRONIUM	Its record names the disease	ClinicalTrials.gov
NCT03948646	Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)	Phase 3	351	2024-05-21	Axillary Hyperhidrosis	SOFPIRONIUM BROMIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03836287	Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)	Phase 3	350	2024-06-06	Axillary Hyperhidrosis	SOFPIRONIUM BROMIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03627468	A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis	Phase 3	300	2023-05-19	Primary Axillary Hyperhidrosis	SOFPIRONIUM BROMIDE	Its record names the disease	ClinicalTrials.gov
NCT03880266	A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis	Phase 2	72	2021-03-15	Palmar Hyperhidrosis	GLYCOPYRRONIUM	Open Targets' reading of its record	ClinicalTrials.gov
NCT03785587	A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis	Phase 2	21	2023-03-14	Primary Axillary Hyperhidrosis	SOFPIRONIUM BROMIDE	Its record names the disease	ClinicalTrials.gov
NCT04924036	Qbrexza Cloths for Hyperhidrosis of Amputation Sites	Phase 2	13	2026-01-22	Amputation, Hyperhidrosis	GLYCOPYRRONIUM	Its record names the disease	ClinicalTrials.gov
NCT01956591	Long Term Results of the Use of Oxybutynin for the Treatment of Hyperhidrosis		1,100		Hyperhidrosis	OXYBUTYNIN	Its record names the disease	ClinicalTrials.gov
NCT01930604	Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis	Phase 2	588		Hyperhidrosis	ONABOTULINUMTOXINA, RIMABOTULINUMTOXINB	Its record names the disease	ClinicalTrials.gov
NCT03416348	Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2	Phase 1	95		Hyperhidrosis	ALUMINUM CHLORIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 22

See all 22 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Active vs Vehicle: deaths from any cause	0 of 180	0 of 171	351	NCT03948646	Trial comparisons
Active vs Vehicle: serious adverse events	1 of 180	0 of 171	351	NCT03948646	Trial comparisons
Active vs Vehicle: deaths from any cause	0 of 173	0 of 176	349	NCT03836287	Trial comparisons
Active vs Vehicle: serious adverse events	1 of 173	0 of 176	349	NCT03836287	Trial comparisons
Gel, 5% vs Gel, 15%: deaths from any cause	1 of 102	0 of 197	299	NCT03627468	Trial comparisons
Gel, 5% vs Gel, 15%: serious adverse events	1 of 102	4 of 197	299	NCT03627468	Trial comparisons
Glycopyrronium Cloths vs Placebo: deaths from any cause	0 of 13	0 of 13	26	NCT04924036	Trial comparisons
Glycopyrronium Cloths vs Placebo: serious adverse events	1 of 13	0 of 13	26	NCT04924036	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26114588	RESULT	1	PubMed
31111409	DERIVED	1	PubMed
23638448	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0000975

GET https://conductscience.org/api/diseases/v1/HP_0000975/targets?page=2

API reference For AI assistants